RecruitingObesity or OverweightType 2 Diabetes
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the efficacy and safety of petrelintide compared with placebo, in conjunction with a reduced-calorie diet and increased physical activity, for weight management in participants living with overweight or obesity and with Type 2 Diabetes (T2D).
Sponsor: Hoffmann-La Roche
You may qualify if…
- ✓ Participants with BMI ≥ 27 kg/m²
- ✓ T2D diagnosis as per World Health Organization (WHO) classification (or other locally applicable standards) with HbA1c ≥ 6.5% to ≤ 10% (48-86 mmol/mol), measured by the central laboratory at screening
- ✓ Stable treatment with either diet and exercise alone, basal insulin, or selected oral glucose-lowering agents, for at least 90 days prior to and during screening
- ✓ History of at least one self-reported unsuccessful dietary effort to lose body weight
You may not qualify if…
- ✕ History or presence of proliferative diabetic retinopathy, or diabetic macular edema
- ✕ Current or previous treatment with petrelintide or any other amylin analog
Where it's recruiting
California
Los Angeles
Virginia
Manassas
Source: ClinicalTrials.gov · NCT07843485 · last updated 2026-10-07